Cormorant Asset Management’s Akero Therapeutics AKRO Stock Holding History

Cormorant Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-115,000	Closed	-$5.37M	–	50
2023 Q2	$5.37M	Buy	+115,000	New	+$5.27M	0.3%	50
2022 Q3	–	Sell	-403,787	Closed	-$3.82M	–	74
2022 Q2	$3.82M	Hold	403,787	–	–	0.29%	56
2022 Q1	$5.73M	Hold	403,787	–	–	0.44%	48
2021 Q4	$8.54M	Sell	403,787 -196,213	-33%	-$4.35M	0.51%	47
2021 Q3	$13.4M	Hold	600,000	–	–	0.54%	45
2021 Q2	$14.9M	Sell	600,000 -142,549	-19%	-$4M	0.51%	47
2021 Q1	$21.5M	Hold	742,549	–	–	0.48%	47
2020 Q4	$19.2M	Sell	742,549 -117,001	-14%	-$3.25M	0.46%	49
2020 Q3	$26.5M	Buy	859,550 +267,011	+45%	+$9.33M	1.02%	32
2020 Q2	$14.8M	Sell	592,539 -50,000	-8%	-$1.14M	0.56%	50
2020 Q1	$13.6M	Sell	642,539 -98,082	-13%	-$2.1M	0.63%	45
2019 Q4	$16.4M	Hold	740,621	–	–	0.66%	41
2019 Q3	$16.8M	Sell	740,621 -27,221	-4%	-$633K	1.03%	32
2019 Q2	$14.7M	Buy	+767,842	New	+$14.6M	0.84%	37

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Cormorant Asset Management's AKRO Position: Q3 2023 in Review

Cormorant Asset Management sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 115,000 shares — an estimated $5.37M sold.

Cormorant Asset Management first reported a position in AKRO in Q2 2019 and held it in 14 quarters. The position peaked at $26.5M in Q3 2020. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

Cormorant Asset Management reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
Cormorant Asset Management sold 115,000 Akero Therapeutics shares in Q3 2023, an estimated $5.37M.
Cormorant Asset Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 14 quarters.
Cormorant Asset Management's Akero Therapeutics position peaked at $26.5M in Q3 2020.
181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.